Session 3: Small Molecule Metabolites in Drug Discovery and Development

Chairs: Faye Vazvaei-Smith, Wenkui Li, Carley Heck, and Scott Obach

Industry Perspective on the Value of ADME Studies and Drug Metabolites

image


Douglas Spracklin, Pfizer




Drug Metabolites and Their Roles in Drug-drug Interactions

image

 

Xinning Yang, U.S. Food and Drug Administration



Vignette 1

image


Simone Schadt,
 Roche




image



Kenichi Umehara, Roche




Vignette 2 

image


Sekhar Surapaneni,
Bristol Myers Squibb




Roundtable Discussion with Speakers

Key:

Complete
Failed
Available
Locked
Session 3: Small Molecule Metabolites in Drug Discovery and Development
Recorded 03/03/2023  |  60 minutes
Recorded 03/03/2023  |  60 minutes Time Stamps: 0:00 - Welcome and Introduction 4:10 - Douglas Spracklin's Presentation: Industry Perspective on the Value of ADME Studies and Drug Metabolites 40:50 - Xinning Yang's Presentation: Drug Metabolites and Their Roles in Drug-drug Interactions 1:31:13 - Simone Schadt's and Kenichi Umehara's Presentation: Vignette 1 2:15:30 - Sekhar Surapaneni's Presentation: Vignette 2 3:05:20 - Panel Discussion 3:46:20 - Closing Slides